CDC42BPA and cancer: The Cdc42 kinase effectors PAK1, PAK2, PAK4, MRCKα, MRCKβ and ACK have all been directly targeted, consistent with cancer mutational data indicating that these proteins show the highest incidence of alterations amongst the Cdc42 effectors [9].